AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19366842
Drug: follicle-stimulating hormone
RxNorm normalized name: Follicle-stimulating hormone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: follicle-stimulating hormone (FSH)
Trial: 11733092
Drug: Pulsatile release
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile release tablets containing 60 mg DIL
Trial: 9390586
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with bupivacaine 0.125% and fentanyl 10 microg/mL
Trial: 9390586
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) with morphine (0.05 mg/kg bolus, 0.02 mg/kg on demand every 10 min)
Trial: 3170796
Drug: Nickel sulfate
RxNorm normalized name: Nickel Sulfate
DrugBank: Nickel sulfate (DB14180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel sulfate in aqueous solutions
Trial: 3170796
Drug: Nickel bioavailability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel bioavailability from earrings and necklace
Trial: 3170796
Drug: Plasma solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma solution for leaching
Trial: 3170796
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution and synthetic sweat
Trial: 18276741
Drug: Rituximab 1
RxNorm normalized name: rituximab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 1 g (2 infusions)
Trial: 8865128
Drug: CDDP 40
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 40 mg/m2 + VP16 100 mg/m2 day 1‐3 (arm A)
Trial: 8865128
Drug: CBDCA 250
RxNorm normalized name: CBDCA
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CBDCA 250 mg/m2 day 1 + CDDP 30 mg/m2 day 2, 3 + VP16 100 mg/m2 day 1‐3 (arm B)
Trial: 1641586
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine once daily
Trial: 29557400
Drug: 5.0 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mm implants
Trial: 29557400
Drug: 10.0 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mm or longer implants
Trial: 25263780
Drug: Control enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control enriched with 100 g/kg of extruded linseed
Trial: 25263780
Drug: Control enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control enriched with 200 g/kg of extruded linseed
Trial: 20145166
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 day 1 every 3 weeks)
Trial: 18042476
Drug: Multivitamin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplementation (mecobalamin 500 mg + multivitamin supplement containing B6 5 mg, folic acid 1 mg)
Trial: 8389269
Drug: Ulinastatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (100 U/mL)
Trial: 3548612
Drug: 50% branched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% branched chain enriched formula (MAA) (Travasol + Branchamin concentrate) at a dose of 1.0-2.0 g/kg/day
Trial: 3548612
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid formula (SAA) (Travasol) at a dose of 1.0-2.0 g/kg/day
Trial: 1382291
Drug: Erythemagenic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythemagenic doses of UVB prior to sensitization with DNCB
Trial: 1382291
Drug: Erythemagenic doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythemagenic doses of UVB
Trial: 29907082
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (Div group)
Trial: 29907082
Drug: 0.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD0.5 group)
Trial: 29907082
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD1.0 group)
Trial: 29907082
Drug: 2.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD2.0 group)
Trial: 22317271
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality based therapy (VRBT)
Trial: 20013927
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g co-amoxiclav (prophylactic dose)
Trial: 20013927
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (control)
Trial: 10730687
Drug: Argatroban 125-microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban 125-microg/kg bolus followed by 4-hour continuous infusion of 2.5 microg/kg/minute (Study 1)
Trial: 10730687
Drug: Argatroban 4-hour
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban 4-hour infusion of 2.5 microg/kg/minute (Study 2)
Trial: 10730687
Drug: Argatroban 5-microg/kg/minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban 5-microg/kg/minute continuous infusion over 4 hours (Study 3)
Trial: 31201218
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days, titrated to a maximum of 15 g over 4 weeks.
Trial: 29717473
Drug: Inhalable doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalable doxorubicin (25 mg/m2)
Trial: 29717473
Drug: Cisplatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (10 mg/m2)
Trial: 22935482
Drug: Albuminuria at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuminuria at 1-2 μg/min
Trial: 12440139
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of INH per day for 6 months
Trial: 7028200
Drug: Naloxone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.3 mg/Kg b.wt.)
Trial: 23816960
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus pemetrexed chemotherapy
Trial: 19430098
Drug: Antiretroviral treatment-experienced
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment-experienced patients
Trial: 19430098
Drug: Antiretroviral treatment-naive
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment-naive patients
Trial: 19430098
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of polymerase domain between treatment-experienced and treatment-naive patients
Trial: 19430098
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of thumb-connection domain between treatment-experienced and treatment-naive patients
Trial: 19430098
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of RNase H domain between treatment-experienced and treatment-naive patients
Trial: 11867826
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (1000 microg daily) for 3 weeks
Trial: 7849886
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (aminophylline)
Trial: 2083923
Drug: S-adenosylmethionine (SAMe)
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosylmethionine (SAMe) 800 mg/day i.v.
Trial: 7211263
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg metoprolol tablet
Trial: 7211263
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg metoprolol tablet
Trial: 7211263
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg metoprolol tablet
Trial: 7211263
Drug: 1% metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metoprolol eye drops administered twice daily for 6 weeks
Trial: 19477358
Drug: Intravenous ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ANP (0.025 microg/kg/min for 3 days)
Trial: 17320191
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for depression
Trial: 14996517
Drug: High-dose clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clarithromycin 500 mg twice daily for 10 days
Trial: 15014819
Drug: Fentanyl 4
RxNorm normalized name: fentanyl 400 MCG Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 4 microg/kg and midazolam 0.04 mg/kg
Trial: 6228473
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine in combination with Hepatitis B immunoglobulin
Trial: 29912819
Drug: Control (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (continued medical therapy)
Trial: 16330766
Drug: Gabapentin (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,800 mg per os, single administration)
Trial: 12059873
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone pulse therapy (group A)
Trial: 12059873
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (group B)
Trial: 8758124
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate 200 micrograms twice daily for six months
Trial: 1736604
Drug: Dipyridamole 75
RxNorm normalized name: dipyridamole 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 75 mg every 8 hours for 2 weeks
Trial: 328328
Drug: Penbutolol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol 25 mg and 50 mg (in 10 patients); 25 mg, 50 mg, and 100 mg (in 2 patients)
Trial: 30762404
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation counseling adjunct (LP1)
Trial: 30762404
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation counseling adjunct (LP2)
Trial: 30762404
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation counseling adjunct (LP3)
Trial: 29083433
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (150kcal, 20g whey protein, 800 IU vitamin D)
Trial: 23001082
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (1 g ampicillin-sulbactam intravenously at anesthesia)
Trial: 22108482
Drug: mf Odontovis
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mf Odontovis Calcium® (calcium salts, Vitamin D, and physiological modulators with antioxidant activity)
Trial: 22108482
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (best treatment without mf Odontovis Calcium®)
Trial: 16167938
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid restriction and BP target of 95-105 mmHg
Trial: 14572325
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension administered with an Adaptive Aerosol Delivery (AAD) system
Trial: 2694097
Drug: Pentoxifylline (Trental)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (Trental) intravenous treatment
Trial: 2694097
Drug: Pentoxifylline (Trental)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (Trental) oral treatment
Trial: 2694097
Drug: Placebo (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control) intravenous treatment
Trial: 18317392
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg prednisone for 5 days, followed by gradually reduced doses for an additional 15 days, and vestibular sedatives for symptomatic relief during the first 5 days.
Trial: 18317392
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and similar vestibular sedatives.
Trial: 8649929
Drug: Agarose gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agarose gel electrophoresis (ethidium bromide staining)
Trial: 8649929
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of specific anti-HCMV antibodies
Trial: 2121016
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) followed by heparin
Trial: 526908
Drug: Rubidazone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubidazone (150 mg/m2 iv over 1 hour)
Trial: 526908
Drug: Adriamycin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (60 mg/m2 iv over 5 minutes)
Trial: 526908
Drug: Adriamycin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (60 mg/m2 iv over 5 minutes) after rubidazone failure
Trial: 27178566
Drug: Dual-coated probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-coated probiotics (Duolac Care), 2 capsules per day, 5 billion bacteria per capsule for 4 weeks
Trial: 25607519
Drug: Supplement (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (vitamin C:1000mg/d; vitamin E: 400 IU/d)
Trial: 19229549
Drug: Carbetocin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 microg IV injection)
Trial: 19229549
Drug: Oxytocin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (10 IU IV infusion over 2 hours)
Trial: 12871368
Drug: Ximelagatran 20
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 20 mg
Trial: 12871368
Drug: Ximelagatran 40
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 40 mg
Trial: 12871368
Drug: Ximelagatran 80
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 80 mg
Trial: 8932891
Drug: Glycine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (0.8 g/kg body weight/day)
Trial: 28419778
Drug: Raltegravir 600
RxNorm normalized name: raltegravir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 600 mg formulation
Trial: 28419778
Drug: Raltegravir 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 3 × 400 mg and 2 × 600 mg dosage forms
Trial: 28419778
Drug: Raltegravir 2
RxNorm normalized name: raltegravir 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 2 × 600 mg formulation
Trial: 28419778
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg
Trial: 28419778
Drug: Raltegravir multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir multiple doses
Trial: 24119859
Drug: Humor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humor therapy intervention provided by ElderClowns for 2-hour sessions, 9-12 times over 12 weeks.
Trial: 24119859
Drug: Humor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humor therapy intervention
Trial: 22249997
Drug: Ecosystem Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecosystem Focused Therapy (EFT)
Trial: 18062519
Drug: Propofol mixed
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol mixed with 2cc of a solution containing phenylephrine 100 microg/cc (total 100 microg)
Trial: 18062519
Drug: Propofol mixed
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol mixed with 2cc of a solution containing phenylephrine 50 microg/cc (total 50 microg)
Trial: 12068252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all tests
Trial: 1742901
Drug: Clindamycin, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin, 150 mg 4 times daily for 10 days
Trial: 6743780
Drug: Zopiclone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone (7.5 mg) + Trimipramine (50 mg)
Trial: 28870242
Drug: Intraoperative wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative wound irrigation with 0.04% polyhexanide (PHX) solution
Trial: 26152221
Drug: Insulin intensive
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin intensive therapy
Trial: 26152221
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with continuation of pre‐CR antidiabetic treatment
Trial: 15567112
Drug: Treatment outcomes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment outcomes (adherence and weight loss)
Trial: 11068858
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x weekly narrow-band UVB treatment
Trial: 11068858
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x weekly narrow-band UVB treatment
Trial: 2439786
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg and 20 mg)
Trial: 2738457
Drug: Sensory Integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Integrative Therapy (SIT) program
Trial: 31740348
Drug: Doravirine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (100 mg per day)
Trial: 31740348
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir (100 mg ritonavir and 800 mg darunavir per day)
Trial: 26165919
Drug: Cognitive-behavioural suicide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural suicide prevention (CBSP) therapy
Trial: 23943299
Drug: Deferred hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred hormonal therapy (D(HT))
Trial: 23943299
Drug: Chemotherapy (CHT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CHT)
Trial: 21930653
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (treated only with antiarrhythmic drugs for 6 weeks)
Trial: 18985146
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (desipramine or fluoxetine) for 8 weeks
Trial: 16870913
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm, decreasing concentrations for a minimum of 24 days)
Trial: 11377900
Drug: Fixed dorzolamide-timolol
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dorzolamide-timolol combination
Trial: 9243107
Drug: Oral 17
RxNorm normalized name: polyoxypropylene (17)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17 beta-estradiol for 6 weeks
Trial: 3448453
Drug: Microencapsulated formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microencapsulated formulation (C)
Trial: 3448453
Drug: Highly buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly buffered formulation (A)
Trial: 3448453
Drug: Cytoprotective formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoprotective formulation (B)
Trial: 3448453
Drug: Plain tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain tablet formulation (D)
Trial: 27565270
Drug: ICS +
RxNorm normalized name: Culturelle Probiotics + Multivitamin Gummies (Mixed Berry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS + LABA treatment